{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.8","upperLimit":"81.8","value":"61.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Interim PET scan positive 1-year PFS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.4","upperLimit":"96.3","value":"89.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Interim PET scan negative 1 year PFS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"1-year PFS is defined as participants who remain free of disease progression or death at one year from study entry. We compared the 1-year PFS of participants with negative results on interim positron emission tomography (PET) scans to those with positive results on interim PET scans.\n\nPFS is defined as the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.","dispersionType":"95% Confidence Interval","groups":[{"description":"Combination chemo and biological therapy\n\nRituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5\n\nFilgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle\n\nEtoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles","id":"OG000","title":"Arm 1-Combination Chemo and Biological Therapy"}],"paramType":"NUMBER","populationDescription":"27 participants had no PET scan.","reportingStatus":"POSTED","timeFrame":"1 year","title":"1 Year Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}